Study | Tumor sizeaa | Liver cirrhosisb | BCLC stage (A/B/C) | Child–Pugh (A/B/C) | Hemorrhagic shockb | UICC stage (I/II/III/IV) | Tumor number (solitaryb) | Type of surger (Minor/Major) | MVIb | Resection marginb | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EH | DH | EH | DH | EH | DH | EH | DH | EH | DH | EH | DH | EH | DH | EH | DH | EH | DH | EH | DH | |
Buczkowski 2006 [5] | 7 ± 4 | 7 ± 3 | 7 (70%) | 5 (50%) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 5/5 | 4/6 | NA | NA | NA | NA |
Ou 2016 [6] | 10 (4–23) | 11 (6–25) | 48 (65.8%) | 37 (63.8%) | NA | NA | NA | NA | 37 (50.7%) | 25 (43.1%) | NA | NA | 1 (100%) | 1 (100%) | 56/17 | 35/23 | 38 (52.0%) | 29 (50.0%) | 51 (69.9%) | 42 (72.4%) |
Ren 2019 [7] | NA | NA | 8 (47.1%) | 14 (51.9%) | 3/9/5 | 7/12/9 | B/C:14/3 | B/C:25/2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Sun 2013 [8] | 7.1 ± 3.5 | 7.1 ± 3.3 | 9 (100.0%) | 9 (90.0%) | NA | NA | NA | NA | NA | NA | NA | NA | 9 (100.0%) | 10 (100.0%) | NA | NA | NA | NA | NA | NA |
Wu 2019 [9] | 6.5 (4.8–8.5) | 8.0 (5.3–10.0) | 15 (50.0%) | 75 (75.0%) | 16/6/7/1 | 59/20/21/0 | B/C:17/13 | B/C:90/10 | 15 (50.0%) | 8 (8.0%) | 16/6/7/1 | 59/20/21/0 | 23 (76.7%) | 77 (77.0%) | 26/4 | 87/13 | 6 (20.0%) | 18 (18.0%) | 29 (96.7) | 97 (97%) |
Yang H 2014 [10] | NA | NA | NA | NA | NA | NA | 10/7/0 | 8/3/0 | NA | NA | 0/15/2/0 | 0/7/4/0 | NA | NA | NA | NA | NA | NA | NA | NA |
Yang T 2013 [1] | NA | NA | NA | NA | NA | NA | 24/4/0 | 108/7/0 | 18 (64%) | 14 (12·2%) | NA | NA | NA | NA | NA | NA | NA | NA | 22 (79%) | 94 (81.7%) |
Zhong 2016 [12] | 8.8 ± 2.3 | 9.0 ± 1.4 | 66 (83.5 %) | 20 (74.1%) | NA | NA | 53/17/9 | 15/9/3 | NA | NA | 15/24/40 | 1/17/9 | 45 (57.0 %) | 10 (37.0 %) | NA | NA | NA | NA | NA | NA |
Zhou 2020 [13] | 7.1 ± 3.9 | 7.3 ± 2.3 | 31 (77.5%) | 15 (75%) | 31/6/1 | 17/3/0 | 31/9/0 | 11/9/0 | 15 (37.5%) | 10 (50%) | NA | NA | 33 (82.5) | 17 (85%) | 35/5 | 17/3 | 14 (35%) | 7 (35%) | 35 (87.5%) | 19 (95%) |